Cancer Gene Therapy
Cancer therapies square measure medicine or different substances that block the growth and unfold of cancer by intrusive with specific molecules (molecular targets) that square measure involved within the growth, progression and unfold of cancer. Many cancer therapies square measure approved by the Food and Drug Administration (FDA) to treat specific styles of cancer. The event of targeted therapies desires the identification of fine targets that is, targets that play a key role in neoplastic cell growth and survival. One approach to distinctive potential targets is to match the amounts of individual proteins in cancer cells with those in traditional cells. Proteins that square measure gift in cancer cells however not traditional cells or that square measure a lot of voluminous in cancer cells would be potential targets, notably if they are famed to worry in cell growth or survival.
RNAI approaches
Drug resistance
Hematopoietic root cell factor transfer
Cellular therapies
Ribozyme technology
Gene delivery systems (viral and non-viral)
DNA synthesis and repair
Related Conference of Cancer Gene Therapy
18th World Congress on Advances in Stem Cell Research and Regenerative Medicine
20th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
18th International Conference on Human Genomics and Genomic Medicine
16th International Conference on Human Genetics and Genetic Diseases
19th International Conference on Genomics & Pharmacogenomics
Cancer Gene Therapy Conference Speakers
Recommended Sessions
- Immunotherapy
- Biomaterials and Biomechanics
- Biomedical Engineering
- Cancer Cell Biology
- Cancer Gene Therapy
- Cell Medical Care Bioprocessing
- Cell Therapy
- Clinical and Translation Research
- Clinical applications of Stem Cells
- Gene Therapy
- Genetic Medicine
- Medical and Nano Biotechnology
- Stem Cell Therapeutics in Modern Era
- Stem Cells Growth and Regeneration
Related Journals
Are you interested in
- Achieving efficient delivery and editing - CRISPR 2025 (Italy)
- Bioinformatics - HUMAN GENOME 2025 (France)
- Cancer and stem cells - CRISPR 2025 (Italy)
- Cancer Genomics - HUMAN GENOME 2025 (France)
- Cognitive Computing - HUMAN GENOME 2025 (France)
- Computational Biology - HUMAN GENOME 2025 (France)
- CRISPR technologies and society - CRISPR 2025 (Italy)
- CRISPR technologies beyond genome editing and gene regulation - CRISPR 2025 (Italy)
- Drug Detection & Development in Bioinformatics - HUMAN GENOME 2025 (France)
- Emergency Medicine - HUMAN GENOME 2025 (France)
- Epigenetics Biomarkers - HUMAN GENOME 2025 (France)
- Genetically Modified Organisms - HUMAN GENOME 2025 (France)
- Genome editing and gene regulation in human health - CRISPR 2025 (Italy)
- Genome editing and gene regulation in industrial bacterial biotechnology - CRISPR 2025 (Italy)
- Genome editing and gene regulation in industrial eukaryotic biotechnology - CRISPR 2025 (Italy)
- Genome Editing Methods and Novel Tools - CRISPR 2025 (Italy)
- Genome Mapping - HUMAN GENOME 2025 (France)
- Genomic Approach to Drug Discovery - HUMAN GENOME 2025 (France)
- Genomic Information in Medicine - HUMAN GENOME 2025 (France)
- Genomic Vaccination - HUMAN GENOME 2025 (France)
- Genomics - HUMAN GENOME 2025 (France)
- Horizons of CRISPR biology - CRISPR 2025 (Italy)
- Human Gene Therapy - HUMAN GENOME 2025 (France)
- Human Genetics - HUMAN GENOME 2025 (France)
- Infectious Diseases - HUMAN GENOME 2025 (France)
- Medicine Genomics - HUMAN GENOME 2025 (France)
- Personalized Medicine - HUMAN GENOME 2025 (France)
- Pharma Genomics & Pharma Informatics - HUMAN GENOME 2025 (France)
- Plant and Animal Biotechnology - CRISPR 2025 (Italy)
- Preimplantation Genetic Diagnosis - HUMAN GENOME 2025 (France)
- Structural Biology and Bioinformatics - CRISPR 2025 (Italy)
- Therapeutic Genome Editing - CRISPR 2025 (Italy)